A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, January 28, 2013
Sanofi Moves Closer to Multiple Sclerosis Drug Approval
Sanofi (NYSE: SNY) announced today that the Food and Drug Administration accepted its supplemental Biologics License Application requesting permission to market Lemtrada for the treatment of relapsing multiple sclerosis.
The active ingredient in Lemtrada was originally approved as Campath to treat leukemia, but Sanofi pulled Campath off the market, with some speculating that this was because the difference between the leukemia dose and the multiple sclerosis dose would have made the drug extremely cheap for the multiple sclerosis patients.
The marketing application is based on two phase 3 studies comparing Lemtrada to Pfizer(NYSE: PFE) and Merck KGaA's Rebif. One study compared the drugs in patients new to treatment while the other tested patients who had relapsed while on a prior therapy.
Sanofi expects a decision from the FDA in the second half of the year. A decision from the Committee for Medicinal Products for Human Use in the EU is expected in the second quarter